Back to Search Start Over

Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey.

Authors :
Flower, Barnaby
Brown, Jonathan C.
Simmons, Bryony
Moshe, Maya
Frise, Rebecca
Penn, Rebecca
Kugathasan, Ruthiran
Petersen, Claire
Daunt, Anna
Ashby, Deborah
Riley, Steven
Atchison, Christina Joanne
Taylor, Graham P.
Satkunarajah, Sutha
Naar, Lenny
Klaber, Robert
Badhan, Anjna
Rosadas, Carolina
Khan, Maryam
Fernandez, Natalia
Source :
Thorax; Dec2020, Vol. 75 Issue 12, p1082-1088, 7p
Publication Year :
2020

Abstract

<bold>Background: </bold>Accurate antibody tests are essential to monitor the SARS-CoV-2 pandemic. Lateral flow immunoassays (LFIAs) can deliver testing at scale. However, reported performance varies, and sensitivity analyses have generally been conducted on serum from hospitalised patients. For use in community testing, evaluation of finger-prick self-tests, in non-hospitalised individuals, is required.<bold>Methods: </bold>Sensitivity analysis was conducted on 276 non-hospitalised participants. All had tested positive for SARS-CoV-2 by reverse transcription PCR and were ≥21 days from symptom onset. In phase I, we evaluated five LFIAs in clinic (with finger prick) and laboratory (with blood and sera) in comparison to (1) PCR-confirmed infection and (2) presence of SARS-CoV-2 antibodies on two 'in-house' ELISAs. Specificity analysis was performed on 500 prepandemic sera. In phase II, six additional LFIAs were assessed with serum.<bold>Findings: </bold>95% (95% CI 92.2% to 97.3%) of the infected cohort had detectable antibodies on at least one ELISA. LFIA sensitivity was variable, but significantly inferior to ELISA in 8 out of 11 assessed. Of LFIAs assessed in both clinic and laboratory, finger-prick self-test sensitivity varied from 21% to 92% versus PCR-confirmed cases and from 22% to 96% versus composite ELISA positives. Concordance between finger-prick and serum testing was at best moderate (kappa 0.56) and, at worst, slight (kappa 0.13). All LFIAs had high specificity (97.2%-99.8%).<bold>Interpretation: </bold>LFIA sensitivity and sample concordance is variable, highlighting the importance of evaluations in setting of intended use. This rigorous approach to LFIA evaluation identified a test with high specificity (98.6% (95%CI 97.1% to 99.4%)), moderate sensitivity (84.4% with finger prick (95% CI 70.5% to 93.5%)) and moderate concordance, suitable for seroprevalence surveys. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00406376
Volume :
75
Issue :
12
Database :
Complementary Index
Journal :
Thorax
Publication Type :
Academic Journal
Accession number :
147067608
Full Text :
https://doi.org/10.1136/thoraxjnl-2020-215732